| Autor: |
Yamada, Risa, Wada, Ayumu, Stickley, Andrew, Yokoi, Yuma, Sumiyoshi, Tomiki |
| Předmět: |
|
| Zdroj: |
International Journal of Neuropsychopharmacology; Apr2023, Vol. 26 Issue 4, p249-258, 10p |
| Abstrakt: |
Background There are ongoing efforts to examine the effect of 5-HT1A receptor partial agonists as an add-on therapy for several symptoms of schizophrenia. By conducting a systematic review and meta-analysis, we evaluated whether augmentation with 5-hydroxtrypatamine (5-HT)1A partial agonists of the azapirone class improves psychotic symptoms and attention/processing speed, a key domain of cognition, in patients with schizophrenia. Methods A literature search was performed from 1987 to February 25, 2022, to identify randomized controlled trials. The standardized mean difference (SMD) with 95% confidence intervals (CI) was calculated when there were 2 or more studies. Seven studies, involving 435 patients, met the inclusion criteria. Results Random-effects model meta-analyses revealed that add-on therapy with buspirone or tandospirone had a significant beneficial effect on overall psychotic symptoms (SMD = –1.13, 95% CI = –1.98 to –0.27) and positive symptoms (SMD = –0.72, 95% CI =–1.31 to –0.12), while the effect on negative symptoms did not reach statistical significance (SMD = –0.93, 95% CI = –1.90 to 0.04). A significant positive effect was also observed on attention/processing speed (SMD = 0.37, 95% CI = 0.12 to 0.61). Conclusions These findings support the idea that some compounds that stimulate 5-HT1A receptors provide an effective pharmacologic enhancer in the treatment of schizophrenia. Further clinical trials are warranted to determine the benefits of the adjunctive use of 5-HT1A partial agonists in ameliorating symptoms and improving functional outcomes in patients with schizophrenia or other psychiatric disorders. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
